EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #05791_C
提升神经元功能的无血清基础培养基
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
-
NeuroCult™ SM1 Neuronal SupplementSupplement (50X) for the serum-free culture of neurons
总览
在无酚红的环境中，培养原代神经元或人多能干细胞（hPSC）来源神经元时，促进而非抑制其神经活性和成熟。BrainPhys™神经元培养基基于Bardy和Gage的配方(Bardy等；PNAS, 2015)，模拟中枢神经系统（CNS）的细胞外环境，以产生更高比例的突触活性神经元。使用BrainPhys™无酚红培养基培养原代神经元，分化和成熟hpsc来源的神经元，记录基于微电极阵列（MEA）的神经元活动，神经元进行活细胞荧光成像，在无激素信号的条件下将体细胞转分化为神经元。为保障细胞在长期无血清培养中存活，BrainPhys™无酚红培养基必须与适当的血清替代添加物结合使用，如NeuroCult™SM1神经元添加物（产品号：#05711）和/或N2补充剂- A（产品号：#07152）。"
亚型
基础培养基，专用培养基
细胞类型
神经细胞，PSC衍生，神经元，多能干细胞
种属
人，小鼠，大鼠
应用
细胞培养，分化，培养
品牌
BrainPhys
研究领域
疾病建模，药物发现和毒理检测，神经科学，干细胞生物学
制剂类别
无血清
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (10)
文献 (2)
Mutations in ACTL6B Cause Neurodevelopmental Deficits and Epilepsy and Lead to Loss of Dendrites in Human Neurons. American journal of human genetics 2019
Abstract
We identified individuals with variations in ACTL6B, a component of the chromatin remodeling machinery including the BAF complex. Ten individuals harbored bi-allelic mutations and presented with global developmental delay, epileptic encephalopathy, and spasticity, and ten individuals with de novo heterozygous mutations displayed intellectual disability, ambulation deficits, severe language impairment, hypotonia, Rett-like stereotypies, and minor facial dysmorphisms (wide mouth, diastema, bulbous nose). Nine of these ten unrelated individuals had the identical de novo c.1027G{\textgreater}A (p.Gly343Arg) mutation. Human-derived neurons were generated that recaptured ACTL6B expression patterns in development from progenitor cell to post-mitotic neuron, validating the use of this model. Engineered knock-out of ACTL6B in wild-type human neurons resulted in profound deficits in dendrite development, a result recapitulated in two individuals with different bi-allelic mutations, and reversed on clonal genetic repair or exogenous expression of ACTL6B. Whole-transcriptome analyses and whole-genomic profiling of the BAF complex in wild-type and bi-allelic mutant ACTL6B neural progenitor cells and neurons revealed increased genomic binding of the BAF complex in ACTL6B mutants, with corresponding transcriptional changes in several genes including TPPP and FSCN1, suggesting that altered regulation of some cytoskeletal genes contribute to altered dendrite development. Assessment of bi-alleic and heterozygous ACTL6B mutations on an ACTL6B knock-out human background demonstrated that bi-allelic mutations mimic engineered deletion deficits while heterozygous mutations do not, suggesting that the former are loss of function and the latter are gain of function. These results reveal a role for ACTL6B in neurodevelopment and implicate another component of chromatin remodeling machinery in brain disease.
iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. Molecular neurodegeneration 2018
Abstract
BACKGROUND Type 2 diabetes (T2D) is a recognized risk factor for the development of cognitive impairment (CI) and/or dementia, although the exact nature of the molecular pathology of T2D-associated CI remains obscure. One link between T2D and CI might involve decreased insulin signaling in brain and/or neurons in either animal or postmortem human brains as has been reported as a feature of Alzheimer's disease (AD). Here we asked if neuronal insulin resistance is a cell autonomous phenomenon in a familial form of AD. METHODS We have applied a newly developed protocol for deriving human basal forebrain cholinergic neurons (BFCN) from skin fibroblasts via induced pluripotent stem cell (iPSC) technology. We generated wildtype and familial AD mutant PSEN2 N141I (presenilin 2) BFCNs and assessed if insulin signaling, insulin regulation of the major AD proteins Abeta$ and/or tau, and/or calcium fluxes is altered by the PSEN2 N141I mutation. RESULTS We report herein that wildtype, PSEN2 N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) show indistinguishable insulin signaling profiles as determined by the phosphorylation of canonical insulin signaling pathway molecules. Chronic insulin treatment of BFCNs of all genotypes led to a reduction in the Abeta$42/40 ratio. Unexpectedly, we found a CRISPR/Cas9-correctable effect of PSEN2 N141I on calcium flux, which could be prevented by chronic exposure of BFCNs to insulin. CONCLUSIONS Our studies indicate that the familial AD mutation PSEN2 N141I does not induce neuronal insulin resistance in a cell autonomous fashion. The ability of insulin to correct calcium fluxes and to lower Abeta$42/40 ratio suggests that insulin acts to oppose an AD-pathophysiology. Hence, our results are consistent with a potential physiological role for insulin as a mediator of resilience by counteracting specific metabolic and molecular features of AD.
更多信息
| 种属 | Human, Mouse, Rat |
|---|---|
| 配方类别 | Serum-Free |
相关产品
-
BrainPhys™神经元培养基提升神经元功能的无血清基础培养基
-
BrainPhys™成像专用培养基无血清神经生理基础培养基，改善神经元活细胞成像和功能
-
N2 添加物-A用于小鼠和人胚胎干细胞和iPS细胞的神经和胰腺分化
-
重组人BDNF脑源性神经营养因子
法律声明:
BrainPhys is a registered trademark of the Salk Institute for Biological Studies, used under exclusive license. 质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
BrainPhys is a registered trademark of the Salk Institute for Biological Studies, used under exclusive license. 质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
